tailieunhanh - Báo cáo y học: " Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. | Respiratory Research BioMed Central Research Open Access Salmeterol fluticasone stable-dose treatment compared with formoterol budesonide adjustable maintenance dosing impact on health-related quality of life David B Price 1 Angela E Williams2 and Sally Yoxall2 Address Department of General Practice and Primary Care University of Aberdeen Foresterhill Health Centre Westburn Road Aberdeen AB25 2AY UK and 2Research and Development GlaxoSmithKline Greenford Road Greenford Middlesex UB6 0HE UK Email David B Price - david@ Angela E Williams - Sally Yoxall - Corresponding author Published 4 July 2007 Received 5 October 2006 Respiratory Research 2007 8 46 doi 1465-9921 -8-46 Accepted 4 July 2007 This article is available from http content 8 1 46 2007 Price et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Improving patients health-related quality of life HRQoL is recognized as a fundamental part of asthma management. The aims of this study were to evaluate the long-term efficacy including symptom-free days and exacerbations and impact on HRQoL of a stable-dose regimen of salmeterol fluticasone propionate SAL FP and an adjustable maintenance dosing AMD regimen of formoterol budesonide FOR BUD where treatment is adjusted based on symptoms SAM40056 . Methods A total of 688 outpatients with asthma receiving regular low-dose inhaled corticosteroids ICS plus a long-acting P2-agonist or medium dose ICS alone participated in this randomized double-blind double-dummy parallel-group 1-year trial which was conducted in 91 centers in 15 countries. Patients were randomized to receive I inhalation of SAL FP 50 250 pg